Value Investing
Value Investing Articles
In the September update on their Quality Growth at a Reasonable Price portfolio, the UBS analysts offer a thorough look at current premium valuations for some top stocks.
Published:
Many investors still want to consider the growth scenario for SodaStream, but perhaps the best way to consider SodaStream for new, would-be investors is as a value stock.
Published:
When you have had a market rally like we have experienced the past two years, there comes a time when stock rotation becomes important.
Published:
Investors should be wondering if the implied upside ahead merits the risk versus reward when it comes to valuation for this hyper-growth stock Palo Alto Networks.
Published:
These were the top analyst stocks to buy under $10 seen in research calls issued this past week.
Published:
Merrill Lynch made some key changes to its oil ratings on Tuesday, specifically to Chevron, ConocoPhillips and Total.
Published:
With less than one-third of the year remaining, many portfolio managers are looking for some outperformance so they can catch up to whatever benchmark they are chasing.
Published:
Last Updated:
These six high-profile downgrades also had some controversy around them because the analysts stuck their necks out and could look pretty silly if the investment thesis turned out to be wrong.
Published:
Many investors believe stocks priced under $10 have much more upside than traditional Dow and S&P 500 stocks.
Published:
PetSmart is not going to be taken private, or so the analyst team at Bank of America Merrill Lynch believes.
Published:
Despite the recently reported breach in online security and the hit that its share price took, Home Depot is likely not as bad off as many investors might think.
Published:
24/7 Wall St. screened for the five highest profile names that made the UBS oversold stocks list this week.
Published:
Is it time for some of the smaller, more agile software companies to end up as targets for bigger companies looking to add additional silos of products to their current offerings?
Published:
Wet Seal shares tanked on Wednesday after the announcement that the company had replaced its CEO.
Published:
Infinity Pharmaceuticals will partner with Abbvie to further develop and commercialize IPI-145, also known as Duvelisib.
Published: